IP Library Granted Patent US 12,371,423
Granted Patent B2
US 12,371,423 · App. 17/983,051 · Granted Jul 29, 2025

Preparation of sufentanil citrate and sufentanil base

Inventors: George Helmut Klemm (Webster Groves, MO); Brian Orr (Webster Groves, MO); Joel McClenaghan (Webster Groves, MO)
Assignee: SpecGX LLC
C07D409/06C07C51/412
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,423
App. No.
17/983,051
Granted
Jul 29, 2025
Kind
B2
Abstract

Provided herein are processes for forming sufentanil citrate from sufentanil base. One process comprises forming sufentanil citrate in the presence of a polar non-aqueous solvent. Other processes comprise forming sufentanil citrate in the presence of water.

Claims (30)

1. A process for preparing solid sufentanil citrate, the process comprising:

(a) forming a first mixture of sufentanil citrate by heating a first portion of sufentanil base with a molar excess of citric acid in water, the first portion of sufentanil base comprising about 10% to about 20% of the total amount of sufentanil base, wherein the volume to mass ratio of water to citric acid in the first mixture is about 8:1 to about 12:1;

(b) cooling the first mixture of sufentanil citrate, wherein the first mixture is substantially free of an oil phase comprising a sufentanil species;

(c) forming a second mixture of sufentanil citrate by heating a second portion of sufentanil base with an approximate molar equivalent of citric acid in water, the second portion of sufentanil base comprising about 80% to about 90% of the total amount of sufentanil base;

(d) adding the second mixture of sufentanil citrate, without cooling, to the first mixture of sufentanil citrate to form a combined mixture;

(e) cooling the combined mixture to form solid sufentanil citrate; and

(f) recovering the solid sufentanil citrate.

2. The process of claim 1 , wherein the molar excess of citric acid to sufentanil base at (a) is about 2.5:1 to about 4.0:1.

3. The process of claim 1 , wherein the molar excess of citric acid to sufentanil base at (a) is about 2.8:1.

4. The process of claim 1 , wherein the heating at (a) is to a temperature from about 70° C. to about 85° C.

5. The process of claim 1 , wherein the cooling at (b) is to a temperature of about 23° C. or less.

6. The process of claim 5 , further comprising maintaining the temperature of the first mixture of sufentanil citrate until (d).

7. The process of claim 1 , wherein the approximate molar equivalent of citric acid to sufentanil base at (c) is from about 0.9:1 to about 1.1:1.

8. The process of claim 1 , wherein the approximate molar equivalent of citric acid to sufentanil base at (c) is about 1:1.

9. The process of claim 1 , wherein the heating at (c) is to a temperature from about 90° C. to about 100° C.

10. The process of claim 1 , wherein the adding at (d) occurs over an extended period of time such that the combined mixture maintains a temperature from about 10° C. to about 23° C.

11. The process of claim 10 , wherein the extended period of time is from about 0.5 hour to about 4 hours.

12. The process of claim 1 , wherein the cooling at (e) is to a temperature from about 0° C. to about 5° C.

13. The process of claim 1 , wherein the recovering at (f) comprises filtering.

14. The process of claim 1 , further comprising drying the solid sufentanil citrate.

15. The process of claim 1 , wherein the first portion of sufentanil base comprises about 15% of the total amount of sufentanil base, and the second portion of sufentanil base comprises about 85% of the total amount of sufentanil base.

16. The process of claim 1 , wherein prior to forming the first mixture of sufentanil citrate, a first solution of citric acid is formed by mixing from about 4 mL to about 6 mL of water per gram of citric acid.

17. The process of claim 1 , wherein prior to forming the second mixture of sufentanil citrate, a second solution of citric acid is formed by mixing from about 12 mL to about 20 ml of water per gram of citric acid.

18. The process of claim 1 , further comprising:

(g) contacting the mixture remaining after recovery of solid sufentanil citrate with a proton acceptor to form a sufentanil base mixture;

(h) cooling the sufentanil base mixture to form solid sufentanil base; and

(i) recovering solid sufentanil base.

19. The process of claim 18 , further comprising contacting solid sufentanil base with a non-polar solvent to form crystalline sufentanil base.

20. The process of claim 18 , wherein the proton acceptor comprises a hydroxide and the non-polar solvent is an alkane.

21. The process of claim 1 , wherein step (a) is accomplished in an inert atmosphere under ambient pressure.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 064709, FRAME 0055 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0860 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 064709/FRAME 0111 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; SPECGX LLC; STRATATECH CORPORATION; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0308 →
SECURITY INTEREST Recorded Aug 25, 2023
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT LLC; STRATATECH CORPORATION; OCERA THERAPEUTICS, INC.; SPECGX LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 064709/0055 →
SECURITY INTEREST Recorded Aug 25, 2023
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT LLC; STRATATECH CORPORATION; OCERA THERAPEUTICS, INC.; SPECGX LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 064709/0070 →
SECURITY INTEREST Recorded Aug 25, 2023
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT LLC; STRATATECH CORPORATION; OCERA THERAPEUTICS, INC.; SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 064709/0111 →
EMPLOYEE CONFIDENTIALITY AND DEVELOPMENT AGREEMENT Recorded Jan 6, 2023
From: KLEMM, GEORGE H.
To: TYCO HEALTHCARE / MALLINCKRODT
Reel/Frame 063140/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2023
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 062294/0681 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2023
From: ORR, BRIAN; MCCLENAGHAN, JOEL
To: MALLINCKRODT LLC
Reel/Frame 062294/0558 →
Continuity (5)
Continuation 17091109 · Nov 6, 2020
Continuation 16254074 · Jan 22, 2019
Continuation 15164483 · May 25, 2016
Provisional Application 62166911 · May 27, 2015
Related Publication 20230074804A1 · Mar 9, 2023
References Cited (56)
US 3998834A · Janssen et al. · 1976 [cited by applicant]
US 4179569A · Janssen et al. · 1979 [cited by applicant]
US 5039804A · Feldman et al. · 1991 [cited by applicant]
US 5489689A · Mathew · 1996 [cited by applicant]
US 6342250B1 · Masters · 2002 [cited by applicant]
US 7074935B2 · Mathew et al. · 2006 [cited by applicant]
US 7208604B2 · Mathew et al. · 2007 [cited by applicant]
US 8299258B2 · Buenger et al. · 2012 [cited by applicant]
US 9338837B2 · Hino · 2016 [cited by applicant]
US 10227335B2 · Klemm et al. · 2019 [cited by applicant]
US 20020106410A1 · Masters · 2002 [cited by applicant]
US 20030152500A1 · Dalziel et al. · 2003 [cited by applicant]
US 20100010031A1 · Yum, II et al. · 2010 [cited by applicant]
US 20100056574A1 · Cheng et al. · 2010 [cited by applicant]
US 20100137604A1 · Buenger et al. · 2010 [cited by applicant]
US 20120071659A1 · Orr et al. · 2012 [cited by applicant]
CN 102060753A · 2011 [cited by applicant]
EP 2455377B1 · 2014 [cited by applicant]
JP H09505277A · 1997 [cited by applicant]
JP 2018515580A · 2018 [cited by applicant]
JP 2021059609A · 2021 [cited by applicant]
WO 9509152A1 · 1995 [cited by applicant]
WO 2008005423A1 · 2008 [cited by applicant]
WO 2008100434A1 · 2008 [cited by applicant]
WO 2016191472A1 · 2016 [cited by applicant]
Chavez K.J., et al., “Characterization of Solvates Formed By Sodium Naproxen and an Homologous Series of Alcohols,” Crystal Growth & Design, 2010, vol. 10 (8), pp. 3372-3377. [cited by applicant]
“Collection of Chemical Engineering Papers,” 1996, vol. 22, No. 4, pp. 750-755. [cited by applicant]
“Common Solvents used in Organic Chemistry: Table of Properties 1,2,3,” American Chemical Society, Division of Organic Chemistry, Retrieved from the Internet: URL: https://www.organicdivision.org/wp-content/uploads/2016… [cited by applicant]
“Crystallization and Purification,” Chapter 12, Synthesis to Production of Pharmaceutical Products, Practical Process, 2nd Edition, Mar. 30, 2014, pp. 404-421. [cited by applicant]
Extended European Search Report for European Application No. 16800663.3, mailed Mar. 20, 2019, 11 Pages. [cited by applicant]
Flick E.W., “Hydrocarbon Solvents,” in Industrial Solvents Handbook, Fifth Edition, Noyes Data Corporation, New Jersey, U.S.A, 1998, pp. 3-37. [cited by applicant]
“Foundation of Basic vol. I Experiment and Information,” Chemical Society of Japan 5th Series of Experimental Chemistry, Lecture 1, Maruzen, Sep. 25, 2003, pp. 162-167. [cited by applicant]
Gattermann L., “The Practical Methods of Organic Chemistry,” London: Macmillan Co., Ltd, 1896, 17 pages. [cited by applicant]
Greco J.B., “Comprehensive Organic Chemistry Experiments for the Laboratory Classroom,” Royal Society of Chemistry, 2017, p. 61. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2016/034091, mailed Dec. 7, 2017, 7 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/034091, mailed Aug. 29, 2016, 9 Pages. [cited by applicant]
Kubota N., et al., “Seeding Effect on Product Crystal Size in Batch Crystallization,” Journal of Chemical Engineering of Japan, 2002, vol. 35 (11), pp. 1063-1071. [cited by applicant]
Morrison K., “Physical Science Level 3,” Pearson Education, Cape Town, 2008, 15 pages. [cited by applicant]
Office Action for Australian Patent Application No. 2016268344, dated Nov. 18, 2019, 3 pages. [cited by applicant]
Office Action for Canadian Patent Application No. 2986764, mailed May 9, 2022, 6 Pages. [cited by applicant]
Office Action for Japanese Application No. 2021-007882 mailed on Sep. 2, 2022, 9 pages. [cited by applicant]
Office Action for Japanese Patent Application No. 2017-561257, dated Mar. 24, 2020, 9 pages. [cited by applicant]
Office Action for Japanese Patent Application No. 2021-007882 mailed on Jan. 18, 2022, 8 pages. [cited by applicant]
Office Action for U.S. Appl. No. 15/164,483, mailed Aug. 10, 2018, 15 pages. [cited by applicant]
Office Action for U.S. Appl. No. 15/164,483, mailed Dec. 27, 2016, 12 pages. [cited by applicant]
Office Action for U.S. Appl. No. 15/164,483, mailed Feb. 9, 2018, 15 pages. [cited by applicant]
Office Action for U.S. Appl. No. 15/164,483, mailed May 26, 2017, 17 pages. [cited by applicant]
Office Action for U.S. Appl. No. 15/164,483, mailed Sep. 22, 2017, 14 pages. [cited by applicant]
Partial Supplementary European Search Report for European Application No. 16800663.3, mailed Dec. 7, 2018, 12 Pages. [cited by applicant]
“Properties of Organic Solvents,” Solvent Polarity Tables, Miller's Home, [online], Retrieved from the Internet: URL: https://sites.google.com/site/miller00828/in/solvent-polarity-table, Retrieved on Aug. 18, 2020, Publ… [cited by applicant]
Stahl P.H., et al., “Handbook of Pharmaceutical Salts: Properties Selection and Use,” Verlag Helvetica Chimica Acta—Zurich, 2002, pp. 191-211. [cited by applicant]
Takada N., “API Form Screening and Selection in Drug Discovery Stage,” Pharm Stage, vol. 6, No. 10, Jan. 15, 2007, 10 pages. [cited by applicant]
Van Daele P.G.H., et al., “Synthetic Analgesics: N-(1-[2-Arylethyl]-4-substituted 4-Piperidinyl) N-Arylalkanamides,” Arzneim—Forschung (Drug Research), XP009074977, 1976, vol. 26 (8), pp. 1521-1531. [cited by applicant]
Van De Streel J., “All Series of Multiple Solvates (Including Hydrates) from the Cambridge Structural Database,” CrystEngComm, 2007, vol. 9, pp. 350-352. [cited by applicant]
Zubrick J.W., “The Organic Chem Lab Survival Manual,” A Student's Guide to Techniques, 4th Edition, John Wiley Sons, New York, 1997, pp. 121-125. [cited by applicant]
1 Office Action for Japanese Application No. 2022-211976, mailed on Jan. 30, 2024, 8 Pages. [cited by applicant]